| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Johanson, V, et al.
(författare)
-
A Randomized, Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) to Assess Patient Preference of Lanreotide Autogel Given by either Self/Partner or Healthcare Professional in NEUROENDOCRINOLOGY, vol 94, issue , pp 29-29
- 2011
-
Ingår i: NEUROENDOCRINOLOGY. - : Karger. ; , s. 703-710
-
Konferensbidrag (refereegranskat)abstract
- Background: Lanreotide Autogel® is supplied in prefilled syringes. Therefore, it is possible for patients with neuroendocrine tumors to use self-/partner-administered injections. The primary objective of this study was to assess the proportion of patients preferring self/partner injections over injections administered by health care professionals, and to describe the impact of self/partner administration on efficacy, safety, and costs. Methods: Of 62 eligible patients, 26 (42%) patients with neuroendocrine tumors treated with a stable dose of lanreotide Autogel 90 mg or 120 mg every 4 weeks agreed to participate in this Phase IV, international, open-label, crossover study, conducted at hospitals in Sweden, Norway, and Denmark. Patients were randomized to two blocks, starting with administration of lanreotide Autogel by either self/partner or a health care professional. Preference for injections administered by self/partner or health care professionals was measured, as well as efficacy, safety, and health care resource utilization (both direct and indirect costs). Results: Of 25 evaluable patients, 22 (88%) preferred self/partner injections, mainly because they experienced increased independence. Based on all patients asked to participate (n = 62), 35% preferred self/partner injections on a regular basis. There was no difference in efficacy or safety between the two administration blocks. Conclusion: Many patients with neuroendocrine tumors prefer self/partner injection of lanreotide Autogel, and are able to self/partner inject without any impact on efficacy or safety. This administration method seems to provide a good alternative for suitable patients to increase patient independence and reduce the number of clinic visits.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Juran, SA, et al.
(författare)
-
Electrophysiological Correlates of Impaired Response Inhibition During Inhalation of Propionic Acid
- 2013
-
Ingår i: JOURNAL OF PSYCHOPHYSIOLOGY. - : Hogrefe Publishing Group. - 0269-8803 .- 2151-2124. ; 27:3, s. 131-141
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Chemosensory stimulation can impair cognitive processing, which we demonstrated previously in human volunteers who showed reduced behavioral accuracy in a go/nogo flanker task during 4-hr, whole-body exposure to 10 ppm propionic acid but not during 0.3 or 5 ppm exposures ( Hey et al., 2009 ). Now we investigated event-related potentials (ERP) in a subgroup of six male volunteers from the same study to identify which cognitive processes were sensitive to propionic acid exposure. The ERP subgroup showed the same increases in chemosensory perceptions and error rate during 10 ppm exposure as the whole group. In addition several exposure-related effects were seen in the ERPs: first there were effects of the absolute level of exposure on ERP components related to inhibition (nogo-P3) and conscious error perception (late PE). We assume that the unpleasant smell of propionic acid mediates these effects. Second, there were effects related to the variability of exposure on components related to processing in conflict and error trials (N2 and error-P3). We assume that exposure variability disturbs processing especially in critical task situations such as conflict and errors. From our results we conclude that ERPs are a valuable tool to examine chemosensory mediated impairment on different cognitive processing states and their neural substrates.
|
|
| 9. |
|
|
| 10. |
|
|
